HUTCHMED China Ltd (HCM) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.003x

Based on the latest financial reports, HUTCHMED China Ltd (HCM) has a cash flow conversion efficiency ratio of 0.003x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX4.12 Million ≈ $501.10 USD) by net assets (GBX1.25 Billion ≈ $152.24K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of HUTCHMED China Ltd for the company's overall valuation and market capitalisation.

HUTCHMED China Ltd - Cash Flow Conversion Efficiency Trend (2005–2025)

This chart illustrates how HUTCHMED China Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

HUTCHMED China Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of HUTCHMED China Ltd ranked by their cash flow conversion efficiency. Explore HCM cash flow quality score to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Archtis Ltd
AU:AR9
-0.252x
Sah Polymers Limited
NSE:SAH
0.014x
Cliq Digital AG
XETRA:CLIQ
0.120x
MiniLuxe Holding Corp
V:MNLX
0.103x
DE&T Co. Ltd
KQ:079810
0.028x
Han Express
KO:014130
-0.034x
Carnavale Resources Limited
F:YBB
-0.009x
Shengli Oil & Gas Pipe Holdings Limited
F:GSG
-0.166x

Annual Cash Flow Conversion Efficiency for HUTCHMED China Ltd (2005–2025)

The table below shows the annual cash flow conversion efficiency of HUTCHMED China Ltd from 2005 to 2025. View HCM stock price and chart for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 GBX1.25 Billion
≈ $152.03K
GBX-64.67 Million
≈ $-7.87K
-0.052x -8137.94%
2024-12-31 GBX771.85 Million
≈ $93.91K
GBX497.00K
≈ $60.47
0.001x -99.78%
2023-12-31 GBX743.39 Million
≈ $90.45K
GBX219.26 Million
≈ $26.68K
0.295x +169.93%
2022-12-31 GBX636.87 Million
≈ $77.49K
GBX-268.60 Million
≈ $-32.68K
-0.422x -114.67%
2021-12-31 GBX1.04 Billion
≈ $126.48K
GBX-204.22 Million
≈ $-24.85K
-0.196x -64.27%
2020-12-31 GBX518.95 Million
≈ $63.14K
GBX-62.07 Million
≈ $-7.55K
-0.120x +53.75%
2019-12-31 GBX312.90 Million
≈ $38.07K
GBX-80.91 Million
≈ $-9.84K
-0.259x -224.54%
2018-12-31 GBX412.25 Million
≈ $50.16K
GBX-32.85 Million
≈ $-4.00K
-0.080x -332.07%
2017-12-31 GBX484.97 Million
≈ $59.01K
GBX-8.94 Million
≈ $-1.09K
-0.018x +60.68%
2016-12-31 GBX204.06 Million
≈ $24.83K
GBX-9.57 Million
≈ $-1.16K
-0.047x +48.90%
2015-12-31 GBX102.28 Million
≈ $12.44K
GBX-9.38 Million
≈ $-1.14K
-0.092x -182.34%
2014-12-31 GBX119.88 Million
≈ $14.59K
GBX13.36 Million
≈ $1.63K
0.111x +132.36%
2013-12-31 GBX104.84 Million
≈ $12.76K
GBX5.03 Million
≈ $611.76
0.048x -74.38%
2012-12-31 GBX83.65 Million
≈ $10.18K
GBX15.66 Million
≈ $1.91K
0.187x +178.34%
2011-12-31 GBX77.33 Million
≈ $9.41K
GBX5.20 Million
≈ $632.88
0.067x +123.36%
2010-12-31 GBX68.81 Million
≈ $8.37K
GBX-19.82 Million
≈ $-2.41K
-0.288x -286.53%
2009-12-31 GBX75.30 Million
≈ $9.16K
GBX11.63 Million
≈ $1.41K
0.154x +191.37%
2008-12-31 GBX84.43 Million
≈ $10.27K
GBX-14.27 Million
≈ $-1.74K
-0.169x -91.86%
2007-12-31 GBX97.61 Million
≈ $11.88K
GBX-8.60 Million
≈ $-1.05K
-0.088x -166.27%
2006-12-31 GBX109.98 Million
≈ $13.38K
GBX-3.64 Million
≈ $-442.64
-0.033x -106.81%
2005-12-31 GBX-28.01 Million
≈ $-3.41K
GBX-13.60 Million
≈ $-1.65K
0.485x --

About HUTCHMED China Ltd

LSE:HCM UK Drug Manufacturers - Specialty & Generic
Market Cap
$21.25 Million
GBX174.68 Billion GBX
Market Cap Rank
#25001 Global
#240 in UK
Share Price
GBX201.00
Change (1 day)
+1.01%
52-Week Range
GBX156.00 - GBX264.00
All Time High
GBX624.00
About

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast c… Read more